24 stories mentioning MPLTUpdated 9d ago
Every FINWIRES story that references MPLT, newest first.
MapLight Therapeutics (MPLT) has an average rating of Buy and mean price target of $32.31, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
MapLight Therapeutics' (MPLT) shares tumbled 68% even after the company said its phase 2 trial of ML-007C-MA in adults with an acute exacerbation of schizophrenia met the primary endpoint at the twice-daily 210/3 mg dose. The once-daily 330/6 mg dose failed to achieve statistical significance on the primary endpoint, showing only numerical improvement over placebo.Intraday volume topped 5.13 million shares, compared with the daily average of 413,234.AiRWA (YYAI) agreed to buy Hongkong Best Life Trade for a base price of $50 million plus potential performance payouts.The stock plunged 74% with volume topping 2.05 million shares, compared with the daily average of 19,642.Nvidia (NVDA) agreed to expand its partnership with South Korean conglomerate SK Group through an AI infrastructure initiative valued at more than $500 billion.Nvidia dropped 5% as volume topped 100.3 million shares, compared with the daily average of 154.5 million.SK hynix (SKHY), part of the SK Group, fell 7.6% as volume topped 40.5 million shares, compared with the daily average of 55.5 million.Price: $11.52, Change: $-25.04, Percent Change: -68.49%
STAK (STAK) shares were down 55% in Monday premarket trading after the earlier session's 602% rally.MapLight Therapeutics (MPLT) stock was down 55% after the company said a phase 2 trial of ML-007C-MA in schizophrenia met its primary endpoint, demonstrating a significant reduction in severity of the condition versus placebo.Profusa (PFSA) shares were down 18% after the company signed a non-binding term sheet to acquire a privately held commercial-stage diagnostics and toxicology testing company.Recon Technology (RCON) stock was down 15%, following the earlier session's 11.6% gain.
Healthcare stocks advanced late Tuesday afternoon with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.4%.The iShares Biotechnology ETF (IBB) climbed 1.3%.In corporate news, Novo Nordisk (NVO) sued rival Eli Lilly (LLY) in the US over alleged "misleading" advertising campaigns for its obesity and diabetes drugs that compete with the Danish drugmaker's products. Novo shares fell 0.7%, and Lilly rose 1.7%.Danaher (DHR) raised its full-year profit guidance as fiscal Q2 results came in stronger than expected. The company lowered the top end of its 2026 revenue growth outlook, and the shares fell 11%.Okyo Pharma (OKYO) shares rose 5.8%. Chairman Gabriele Cerrone increased his stake in the company to 10.9 million shares, or 20.5% of the issued shares, with the purchase of 25,000 shares at $1.40 each.MapLight Therapeutics (MPLT) is seen having meaningful upside in the ML-007 Phas2 2 schizophrenia trial readout with data expected in mid-August, UBS Securities said. MapLight shares rose 4.1%.
Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index rising 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.3%.In corporate news, MapLight Therapeutics (MPLT) is seen having meaningful upside in the upcoming ML-007 Ph2 schizophrenia trial readout, with the study completed on June 4th and data expected in mid-August, UBS said in a note. MapLight shares rose 3%.
MapLight Therapeutics (MPLT) is seen having meaningful upside in the upcoming ML-007 Ph2 schizophrenia trial readout, with the study completed on June 4th and data expected in mid-August, UBS said in a note Tuesday.The bank said investors are primarily focused on whether ML-007 can demonstrate a clean tolerability profile, with low rates of vomiting and nausea that can differentiate it from Cobenfy.UBS said the potential advantages of once-daily dosing and no food restrictions are particularly important in the schizophrenia patient group given challenges with adherence and cognitive impairment, adding that better tolerability could be a win even with similar efficacy.UBS maintained a buy rating and raised price target to $52 from $48.Price: $37.00, Change: $+1.01, Percent Change: +2.81%
MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $43.23, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $37.06, Change: $+1.07, Percent Change: +2.96%
Anatol Kreitzer, Chief Discovery Officer, on July 15, 2026, sold 36,284 shares in Maplight Therapeutics (MPLT) for $1,345,894. Following the Form 4 filing with the SEC, Kreitzer has control over a total of 174,906 voting common shares of the company, with 174,906 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123826000010/xslF345X05/form4-07202026_060701.xml
Jonathan Gillis, Chief Accounting Officer and Interim Chief Financial Officer, on July 15, 2026, sold 36,979 shares in Maplight Therapeutics (MPLT) for $1,372,668. Following the Form 4 filing with the SEC, Gillis has control over a total of 144,240 voting common shares of the company, with 144,240 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000170995426000010/xslF345X05/form4-07202026_060704.xml
Erin Pennock Foff, Chief Medical Officer, on July 15, 2026, sold 47,158 shares in MapLight Therapeutics (MPLT) for $1,734,490. Following the Form 4 filing with the SEC, Foff has control over a total of 298,901 voting common shares of the company, with 298,901 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123326000012/xslF345X05/form4-07182026_010714.xml
Christopher A. Kroeger, Director, Chief Executive Officer, on July 15, 2026, sold 147,639 shares in MapLight Therapeutics (MPLT) for $5,443,722. Following the Form 4 filing with the SEC, Kroeger has control over a total of 1,347,645 voting common shares of the company, with 1,246,455 shares held directly and 101,190 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000165891826000014/xslF345X05/form4-07182026_010744.xml
MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $39.55, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.3%.Definium Therapeutics (DFTX) shares were up more than 60% after the company said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, along with all key secondary efficacy endpoints.MapLight Therapeutics' (MPLT) phase 2 trial of ML-004 in autism spectrum disorder failed to meet its primary endpoint in social communication, the company said. MapLight Therapeutics stock was up 1.6% premarket.
MapLight Therapeutics (MPLT) has an average rating of buy and mean price target of $37.90, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
MapLight Therapeutics, Inc. (MPLT) has an average rating of buy and mean price target of $36.78, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Christopher A. Kroeger, Director, Chief Executive Officer, on May 18, 2026, sold 118,235 shares in MapLight Therapeutics (MPLT) for $3,215,000. Following the Form 4 filing with the SEC, Kroeger has control over a total of 1,394,094 voting common shares of the company, with 1,394,094 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000165891826000012/xslF345X05/form4-05192026_010517.xml
Vishwas Setia, Chief Financial Officer, on May 04, 2026, sold 36,371 shares in Maplight Therapeutics (MPLT) for $1,024,719. Following the Form 4 filing with the SEC, Setia has control over a total of 356,256 voting common shares of the company, with 356,256 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202125626000008/xslF345X05/form4-05062026_080509.xml
Erin Pennock Foff, Chief Medical Officer, on May 04, 2026, sold 50,280 shares in Maplight Therapeutics (MPLT) for $1,427,594. Following the Form 4 filing with the SEC, Foff has control over a total of 350,497 voting common shares of the company, with 350,497 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000202123326000008/xslF345X05/form4-05062026_080507.xml
James Woodruff Lillie, Chief Scientific Officer, on May 04, 2026, sold 51,707 shares in Maplight Therapeutics (MPLT) for $1,468,251. Following the Form 4 filing with the SEC, Lillie has control over a total of 243,450 voting common shares of the company, with 243,450 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000172874626000008/xslF345X05/form4-05062026_080505.xml
Kristopher Hanson, General Counsel, on May 04, 2026, sold 13,917 shares in Maplight Therapeutics (MPLT) for $388,177. Following the Form 4 filing with the SEC, Hanson has control over a total of 176,248 voting common shares of the company, with 176,248 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1770069/000178997026000008/xslF345X05/form4-05062026_080503.xml
Showing 1-20 of 24
